Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL

February 20, 2009

PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ — Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,
announces that it has signed an agreement with UCB to acquire the worldwide
rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (excluding the
USA, Canada and Barbados) used for the treatment of Attention Deficit
Hyperactivity Disorder (ADHD).

EQUASYM XL is approved and marketed in 10 countries (outside the USA,
Canada, and Barbados), and EQUASYM IR is currently approved and marketed in
four countries. In 2008 the products generated aggregate net sales of EUR16.9
in these territories.

This acquisition will broaden the scope of Shire’s ADHD portfolio and
will facilitate immediate access to the European ADHD market as well as
provide Shire the opportunity to enter additional world markets. EQUASYM will
allow Shire to build on its status as the leader in the United States ADHD
market with patients and customers in Europe and establishes a solid bridge
for Shire’s other ADHD treatments in territories outside of the United
. VYVANSE(R) (lisdexamfetamine dimesylate), used for the treatment of
ADHD in pediatric and adult patients, was launched by Shire in the United
in July 2007 and is in Phase 3 trials in Europe.

As part of this transaction, approximately 20 sales and sales management
personnel will transfer to Shire, providing an established sales force for
EQUASYM and other potential ADHD products.

Michael Cola, President of Shire’s Specialty Pharmaceuticals business,

“The acquisition of the EQUASYM franchise accelerates the establishment
of Shire’s ADHD presence in markets outside of North America. Our expertise
and portfolio of ADHD products will provide a strong foundation from which we
can offer innovative treatments for adults and children with ADHD.”

Shire will make a cash payment to UCB of EUR55 million for the
acquisition of global rights (ex-USA, Canada and Barbados) on completion of
the transaction. The acquisition is expected to be earnings neutral for 2009
and accretive from 2010 on a Non GAAP basis. In addition, small milestone
payments may become payable in 2009 and 2010 if certain net sales targets are
met. The acquisition is subject to standard closing conditions.

About ADHD

ADHD is one of the most common psychiatric disorders in children and
adolescents. Worldwide prevalence of ADHD is estimated at 5.3 percent (with
large variability), according to a comprehensive systematic review of this
topic published in 2007 in the American Journal of Psychiatry. In the United
, approximately 7.8 percent of all school-aged children, or about 4.4
million children aged 4 to 17 years, have been diagnosed with ADHD at some
point in their lives, according to the U.S. Centers for Disease Control and
Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US
adults aged 18-44 (~ 9.8 million) based on results from the National
Comorbidity Survey Replication.

ADHD is a psychiatric behavioral disorder that manifests as a persistent
pattern of inattention and/or hyperactivity-impulsivity that is more frequent
and severe than is typically observed in individuals at a comparable level of
development. The specific aetiology of ADHD is unknown and there is no single
diagnostic test for this syndrome. Adequate diagnosis requires the use of
medical and special psychological, educational and social resources,
utilizing diagnostic criteria such as Diagnostic and Statistical
Manual(TM)-IV (DSM-IV) or International Classification of Diseases 10

Although there is no “cure” for ADHD, there are accepted treatments that
specifically target its symptoms. Standard treatments include educational
approaches, psychological, or behavioural modification, and medication.


Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire’s in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website:

ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the Company’s results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of
pharmaceutical and biopharmaceutical research, development, approval,
reimbursement, manufacturing and commercialization of the Company’s Specialty
Pharmaceutical and Human Genetic Therapies products, as well as the ability
to secure new products for commercialization and/or development; government
regulation of the Company’s products; the Company’s ability to manufacture
its products in sufficient quantities to meet demand; the impact of
competitive therapies on the Company’s products; the Company’s ability to
register, maintain and enforce patents and other intellectual property rights
relating to its products; the Company’s ability to obtain and maintain
government and other third-party reimbursement for its products; the
Company’s ability to successfully integrate its stake in Jerini AG, as well
as realize the anticipated benefits of the acquisition; and other risks and
uncertainties detailed from time to time in the Company’s filings with the
Securities and Exchange Commission

    Notes to Editors

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World)
    Eric Rojas (North America)

    Matthew Cabrey (North America)

SOURCE Shire Plc

Source: newswire

comments powered by Disqus